Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dubodencel - Diakonos Oncology

Next Previous
Drug Profile

Dubodencel - Diakonos Oncology

Alternative Names: Dendritic cell cancer vaccine - Diakonos Oncology; DOC-1021

Latest Information Update: 13 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Diakonos Research
  • Developer Baylor College of Medicine; Diakonos Oncology
  • Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I/II Multiple myeloma
  • Phase I Adenocarcinoma; Sarcoma
  • Discontinued Prostate cancer; Triple negative breast cancer

Most Recent Events

  • 23 Feb 2026 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater, Metastatic disease, Combination therapy, Inoperable/Unresectable) in USA (Parenteral) (NCT07288112)
  • 17 Dec 2025 Diakonos Oncology plans a phase I/II trial for Malignant-melanoma (Metastatic disease, Second-line therapy or greater, Combination therapy, Inoperable/unresectable) in January 2026 (NCT07288112)
  • 07 Nov 2025 Phase-I development is ongoing in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top